Stockreport

Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push [Globe and Mail, The (Toronto, Canada)]

Immunic, Inc.  (IMUX) 
PDF As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor p [Read more]